The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

OBJECTIVE The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression. Subsequent reports of decreased systolic function,...

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Does Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study

Background: Mesenchymal stem cells (MSCs) with their potential to differentiate into mesodermal and non-mesodermal lineages have several immunomodulatory characteris-tics. These properties make them promising tools in cell and gene therapy. Objective: To evaluate the potential therapeutic applications of autologous MSC in improving clinical manifestations of MS patients. Methods: Ten patients w...

Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

2010;74;691 Neurology Hans D. Katzberg, Ahmir H. Khan and Yuen T. So of Neurology Technology Assessment Subcommittee of the American Academy evidence-based review) : Report of the Therapeutics and Assessment: Symptomatic treatment for muscle cramps (an January 10, 2013 This information is current as of http://www.neurology.org/content/74/8/691.full.html located on the World Wide Web at: The onl...

P67: The Effect of Melatonin on EDSS and Fatigue in Multiple Sclerosis

Multiple Sclerosisis (MS) is a common demylinating disease of CNS that inflammation and stress oxidative processes have an important role in clinical courses and progression of it. Suppressing the antigen-presenting capacity of glial cells seems a convinient way of reducing inflammatory activity in MS. The aim of the present study was to determine the anti-inflamatory effects of Melatonin on fa...